{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"SBRT-AMICO","nct_id":"NCT05915442","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=sbrt-amico-nct05915442. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"SBRT-AMICO","arms":[{"description":"Subjects with metastatic prostate cancer will receive quemliclustat and etrumadenant for 4 weeks prior to metastasis-directed SBRT (Stereotactic Body Radiation Therapy). Within one week of completing SBRT, subjects will also start zimberelimab.","label":"Treatment with quemliclustatm, etrumadenant, zimberelimab and SBRT","type":"EXPERIMENTAL"}],"collaborators":["Arcus Biosciences, Inc."],"completion_date":{"date":"2028-12","type":"ESTIMATED"},"conditions":["Oligometastatic Prostate Cancer"],"enrollment":{"count":23,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Quemliclustat","otherNames":["AB680"],"type":"DRUG"},{"name":"Etrumadenant","otherNames":["AB928"],"type":"DRUG"},{"name":"Zimberelimab","otherNames":["AB122"],"type":"DRUG"},{"name":"Stereotactic Body Radiation Therapy","otherNames":["SBRT"],"type":"RADIATION"}],"last_update":"2025-05-20","lead_sponsor":"Catherine Spina","official_title":"Phase II Single Arm Study Testing SBRT, Adenosine Signaling Modulation (AB680, AB928), and Immune Checkpoint Inhibition (AB122) for Men With Hormone Sensitive Oligometastatic Prostate Cancer","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-12-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Biochemical recurrence-free survival at 12-months","timeFrame":"12 months"}],"references":[],"start_date":{"date":"2023-07-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT05915442"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/sbrt-amico-nct05915442"}